Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphomaOlalekan O. Oluwole, Tom van Meerten, Krimo Bouabdallah et al.|British Journal of Haematology|2021Cited by 217
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment studyMichaël Loschi, Régis Peffault de Latour, Raphaël Porcher et al.|American Journal of Hematology|2015Cited by 148
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O. Oluwole, Tom van Meerten, Édouard Forcade et al.|Bone Marrow Transplantation|2024Cited by 26
Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)Olalekan O. Oluwole, Tom van Meerten, Krimo Bouabdallah et al.|Transplantation and Cellular Therapy|2021Cited by 7
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)Olalekan O. Oluwole, Tom van Meerten, Édouard Forcade et al.|Blood|2021Cited by 7